Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
РУДН, Москва
Список исп. литературыСкрыть список 1. Bishara E et al. Oncemonthly paliperidone injection for the treatment of schizophrenia. Neuropsychiatric Disease and Treatment 2010; 6: 561–72. 2. Gopal S et al. Efficacy and safety of longacting injectable paliperidone palmitate relative to longacting injectable haloperidol, bromperidol and fluphenazine decanoate for longterm treatment in patients with schizophrenia using number needed to treat and number needed to harm. Poster presented at the American Society for Experimental NeuroTherapeutics (ASENT) 12th Annual Meeting US 2010; 46. 3. Gopal S et al. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Current Medical Research & Opinion 2010; 26 (2): 377–87. 4. Gopal S et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, doubleblind, placebocontrolled, Doseresponse study. International Clinical Psychopharmacology 2010; 25 (5): 247–56. 5. Gopal S et al. A 52 week openlabel study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol 2010; doi: 10.1177/0269881110372817 6. Elan Drug Technologies. Available. November 2010; at: http://www. elandrugtechnologies.com/nanocrystal_technology Accessed 25 7. Owen RT et al. Paliperidone palmitate injection: its efficacy, safety and tolerability in schizophrenia. Drugs of today 2010; 46 (7): 463–71. 8. Cleton A et al. Evaluation of the pharmacokinetic profile of deltoid versus gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia. Poster presented at ASCPT. Orlando, FL 2008; 25. 9. Cleton A et al. Assessment of the dose proportionality of paliperidone palmitate 25, 50, 100 and 150 mg eq., a new longacting injectable antipsychotic following administration in the deltoid or gluteal muscles. Clin Pharmacol Ther 2008; 83: 31. 10. Hoy SM et al. Intramuscular paliperidone palmitate. CNS Drugs 2010; 24 (3): 227–44. 11. Kramer M et al. Paliperidone palmitate, a potential longacting treatment for patients with schizophrenia. Results of a randomized, doubleblind, placebocontrolled efficacy and safety study. International Journal of Neuropsychopharmacology 2009; 27: 113. 12. Pandina GJ et al. A randomised, placebocontrolled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 2010; 30: 235–44. 13. Pandina GJ et al. A randomized, doubleblind, comparative study of flexible doses of paliperidone palmitate and risperidone longacting therapy in patients with schizophrenia. Poster presented at the 48th ACNP Annual Meeting 2009; Florida, USA. 14. Nasrallah HA et al. A controlledevidence based trial of paliperidone palmitate, a Longacting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 2010; 35 (10): 207–82. 15. Hough D et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Progress in NeuroPsychopharmacology & Biological Psychiatry 2009; 33: 1022–31. 16. Hough D et al. Paliperidone palmitate maintenance treatment in delaying the Timetorelapse in patients with schizophrenia: A randomized, doubleblind Placebocontrolled study. Schizophrenia Research 2010; 116 (23): 107–17. 17. Fleischhacker W et al. Optimization of the dosing strategy for the longacting Injectable antipsychotic paliperidone palmitate: results of two randomized doubleblind Studies and population pharmacokinetic simulations. Poster presented at the 47th annual meeting of the American College of Neuropsychopharmacology (ACNP). Scottsdale, Arizona, USA 2008; 711. 18. Samtani M et al. Initiation dosing of deltoid intramuscular paliperidone palmitate in schizophrenia: pharmacokinetic rationale based on modeling and simulation. Poster presented at the 162nd annual meeting of the American Psychiatric Association (APA). San Francisco, California, USA 2009; 1621. 19. Coppola D et al. Longterm safety, tolerability and pharmacokinetics of paliperidone palmitate: a oneyear openlabel study in patients with schizophrenia. Poster presented at the Annual meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT). Atlanta, Georgia, USA 2010; 1720.